Sarah Shaver, - Medicare in Tiverton, RI

Sarah Shaver, is a medicare enrolled "Physical Therapy Assistant" provider in Tiverton, Rhode Island. Her current practice location is 300 Industrial Way Fl 3, Tiverton, Rhode Island. You can reach out to her office (for appointments etc.) via phone at (401) 726-7100.

Sarah Shaver is licensed to practice in Rhode Island (license number PT03531) and she also participates in the medicare program. She does not accept medicare assignments directly but she may accept medicare through third-party (refer to Reassignment section below) and may also prescribe medicare part D drugs. Her NPI Number is 1053830307.

Contact Information

Sarah Shaver,
300 Industrial Way Fl 3,
Tiverton, RI 02878-3133
(401) 726-7100
(401) 240-1410



Healthcare Provider's Profile

Full NameSarah Shaver
GenderFemale
SpecialityPhysical Therapy Assistant
Location300 Industrial Way Fl 3, Tiverton, Rhode Island
Accepts Medicare AssignmentsMedicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs.
  NPI Data:
  • NPI Number: 1053830307
  • Provider Enumeration Date: 09/18/2017
  • Last Update Date: 11/11/2022
  Medicare PECOS Information:
  • PECOS PAC ID: 7810262490
  • Enrollment ID: I20171006002569

Medical Identifiers

Medical identifiers for Sarah Shaver such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1053830307NPI-NPPES

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
225100000XPhysical Therapist (* (Not Available))Secondary
225200000XPhysical Therapy Assistant PT03531 (Rhode Island)Primary

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Sarah Shaver allows following entities to bill medicare on her behalf.
Provider NameBenchmark Physical Therapy Of Oregon Llc
Provider TypePart B Supplier - Physical/occupational Therapy Group In Private Practice
Provider IdentifiersNPI Number: 1801257191
PECOS PAC ID: 0143510602
Enrollment ID: O20160613001008

News Archive

Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS).

Pesticide use can speed the transmission of schistosomiasis

Widespread use of pesticides and other agrochemicals can speed the transmission of the debilitating disease schistosomiasis, while also upsetting the ecological balances in aquatic environments that prevent infections, finds a new study led by researchers at the University of California, Berkeley.

Antibody that targets CXCR6 prevents and reverses multiple sclerosis in mouse model

Multiple sclerosis, an autoimmune disorder, is known to be driven by "helper" T cells, white blood cells that mount an inflammatory attack on the brain and spinal cord. A new study from Boston Children's Hospital pinpoints the specific subgroup of helper T cells that cause MS, as well as a protein on their surface, called CXCR6, that marks them.

Pfizer, Medivation announce results of two dimebon Phase 3 trials in AD patients

Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.

Researchers identify genes that influence degeneration of the hippocampus

In a genome-wide association (GWA) study, researchers from Boston University Schools of Medicine (BUSM) and Public Health (BUSPH) have identified several genes which influence degeneration of the hippocampus, the part of the brain most associated with Alzheimer disease (AD).

Read more Medical News

› Verified 3 days ago

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Sarah Shaver is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Sarah Shaver,
4 Richmond Sq Ste 200,
Providence, RI 02906-5117

Ph: (401) 433-4172
Sarah Shaver,
300 Industrial Way Fl 3,
Tiverton, RI 02878-3133

Ph: (401) 726-7100

News Archive

Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS).

Pesticide use can speed the transmission of schistosomiasis

Widespread use of pesticides and other agrochemicals can speed the transmission of the debilitating disease schistosomiasis, while also upsetting the ecological balances in aquatic environments that prevent infections, finds a new study led by researchers at the University of California, Berkeley.

Antibody that targets CXCR6 prevents and reverses multiple sclerosis in mouse model

Multiple sclerosis, an autoimmune disorder, is known to be driven by "helper" T cells, white blood cells that mount an inflammatory attack on the brain and spinal cord. A new study from Boston Children's Hospital pinpoints the specific subgroup of helper T cells that cause MS, as well as a protein on their surface, called CXCR6, that marks them.

Pfizer, Medivation announce results of two dimebon Phase 3 trials in AD patients

Pfizer Inc. and Medivation, Inc. today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.

Researchers identify genes that influence degeneration of the hippocampus

In a genome-wide association (GWA) study, researchers from Boston University Schools of Medicine (BUSM) and Public Health (BUSPH) have identified several genes which influence degeneration of the hippocampus, the part of the brain most associated with Alzheimer disease (AD).

Read more News

› Verified 3 days ago



Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.